CAJ | 학술논문

分析2006年3月至2011年10月间收治入院104例宫颈鳞状细胞癌患者(FIGO临床分期:Ⅰb2～Ⅱb期),一组50例,给予术前静脉新辅助化疗(新辅助化疗组);另一组54例,给予介入动脉化疗+双侧子宫动脉栓塞术(介入化疗组).依据WHO实体肿瘤评价标准,于化疗结束2周肿瘤大小变化为完全缓解或部分缓解者实施手术治疗,反之则实施放射治疗.化疗后,新辅助化疗组手术率为70％(35例),介入化疗组为87％(47例)(P＜0.05).新辅助化疗组术后有6例(17％)发生脉管瘤栓,8例(23％)发生淋巴结转移,手术切缘阳性1例(3％).介入治疗组分别为7例(15％),9例(21％),1例(2％),差异无统计学意义(P＞0.05).术前化疗对宫颈鳞状细胞癌Ⅰ b2～Ⅱb期(肿瘤直径＞4 cm)治疗有效,不良反应发生率低.
분석2006년3월지2011년10월간수치입원104례궁경린상세포암환자(FIGO림상분기:Ⅰb2～Ⅱb기),일조50례,급여술전정맥신보조화료(신보조화료조);령일조54례,급여개입동맥화료+쌍측자궁동맥전새술(개입화료조).의거WHO실체종류평개표준,우화료결속2주종류대소변화위완전완해혹부분완해자실시수술치료,반지칙실시방사치료.화료후,신보조화료조수술솔위70％(35례),개입화료조위87％(47례)(P＜0.05).신보조화료조술후유6례(17％)발생맥관류전,8례(23％)발생림파결전이,수술절연양성1례(3％).개입치료조분별위7례(15％),9례(21％),1례(2％),차이무통계학의의(P＞0.05).술전화료대궁경린상세포암Ⅰ b2～Ⅱb기(종류직경＞4 cm)치료유효,불량반응발생솔저.
A total of 104 patients with cervical squamous cell cancer (Figo Ⅰ b2-Ⅱ b) were recruited during March 2006 and October 2011.One group (A,n =50) received preoperative intravenous neoadjuvant chemotherapy while another group (B,n =54) had interventional arterial chemotherapy plus bilateral uterine artery embolization.Surgery was performed for those with a change of cancer size either as complete or partial remission at Week 2 post-chemotherapy according to the WHO evaluation criteria.Otherwise radiotherapy was implemented.The ratio of surgery after chemotherapy was 70％ (n =35) in Group A versus 87％ (n =47) in Group B (P ＜ 0.05).For Group A,there were blood vessel invasion (n =6,17％),lymph node metastasis (n =8,23％) and positive margin (n =1,3％).For Group B,(n =7,15％),(n =9,21％) and (n =1,2％).There was no significant inter-group statistic difference (P ＞ 0.05).Preoperative chemotherapy is effective for cervical squamous cancer (tumor diameter ＞ 4 cm)with fewer side effects.